Soleno Therapeutics, Inc. $SLNO Shares Acquired by Profund Advisors LLC

Profund Advisors LLC increased its position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 78.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,371 shares of the company’s stock after purchasing an additional 15,532 shares during the period. Profund Advisors LLC owned 0.07% of Soleno Therapeutics worth $1,638,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in shares of Soleno Therapeutics in the 2nd quarter worth $25,000. Danske Bank A S acquired a new position in Soleno Therapeutics during the third quarter worth about $27,000. Aster Capital Management DIFC Ltd bought a new stake in Soleno Therapeutics in the third quarter worth about $37,000. Quarry LP acquired a new stake in Soleno Therapeutics in the 3rd quarter valued at about $47,000. Finally, Quantbot Technologies LP bought a new position in shares of Soleno Therapeutics during the 3rd quarter valued at about $67,000. 97.42% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on SLNO shares. HC Wainwright downgraded shares of Soleno Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the stock from $100.00 to $53.00 in a report on Wednesday, April 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. Cantor Fitzgerald reissued a “neutral” rating on shares of Soleno Therapeutics in a research note on Tuesday. Lifesci Capital lowered Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Finally, TD Cowen downgraded Soleno Therapeutics from a “buy” rating to a “hold” rating and reduced their target price for the company from $85.00 to $53.00 in a report on Tuesday, April 7th. Three equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Soleno Therapeutics has a consensus rating of “Hold” and a consensus target price of $76.67.

Soleno Therapeutics Stock Performance

Soleno Therapeutics stock opened at $53.01 on Thursday. Soleno Therapeutics, Inc. has a 52 week low of $29.43 and a 52 week high of $90.32. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.32 and a current ratio of 5.62. The firm has a market capitalization of $2.76 billion, a price-to-earnings ratio of 29.95 and a beta of -2.22. The company has a 50 day moving average price of $45.79 and a 200 day moving average price of $45.46.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to the consensus estimate of $88.55 million. Soleno Therapeutics had a net margin of 33.70% and a return on equity of 22.85%. Research analysts forecast that Soleno Therapeutics, Inc. will post 3.67 EPS for the current year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.